Novelos Therapeutics And Musc Peer Reviewed Article Published In Expert Opinion On Investigational Drugs

"NOV-002, a Mimetic of Glutathione Disulfide"

Newton, Massachusetts, (PresseBox) - Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos' peer reviewed article, based on the collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina(MUSC), has been published in Expert Opinion on Investigational Drugs [Volume 17, Issue 7, pages 1075-1083, 2008]. This article describes clinical results as well as findings in cellular and animal model systems that demonstrate the ability of NOV-002 to influence redox balance in and on cells, resulting in a constellation of effects on redox-sensitive cell processes and functions.
NOV-002 is the subject of an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, having also demonstrated positive results in Phase 2 trials for other oncology indications.

"We are very pleased to have another peer reviewed publication, continuing to establish cellular redox modulation as the fundamental mechanism of action of NOV-002," said Christopher Pazoles, Ph.D., Vice President of Research & Development of Novelos. "This article strengthens the connection between NOV-002 and an emerging literature that has shown redox status to be a key regulator of signal pathway activation, cell proliferation, cytoskeleton changes and other cell functions that may relate to NOV-002's unique therapeutic profile, which is also described in the article."

The article is available at www.novelos.com 'Our Products', 'NOV-002' section.

Novelos Therapeutics, Inc.

Novelos Therapeutics, Inc. is a biopharmaceutical company commercializing oxidized glutathione-based compounds for the treatment of cancer and hepatitis. NOV-002, the lead compound currently in Phase 3 development for lung cancer under a SPA and Fast Track, acts together with chemotherapy as a chemoprotectant and a chemopotentiator. NOV-002 is also in Phase 2 development for chemotherapy-resistant ovarian cancer and early-stage breast cancer.
NOV-205 acts as a hepatoprotective agent with immunomodulating and anti-inflammatory properties. NOV-205 is in Phase 1b development for chronic hepatitis C non-responders. Both compounds have completed clinical trials in humans and have been approved for use in the Russian Federation where they were originally developed. For additional information about Novelos please visit www.novelos.com

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.